AVCT vs. ERGO, SLN, OXB, PRTC, HZD, VRP, FARN, ARIX, BVXP, and 4BB
Should you be buying Avacta Group stock or one of its competitors? The main competitors of Avacta Group include Ergomed (ERGO), Silence Therapeutics (SLN), Oxford Biomedica (OXB), PureTech Health (PRTC), Horizon Discovery Group plc (HZD.L) (HZD), Verona Pharma plc (VRP.L) (VRP), Faron Pharmaceuticals Oy (FARN), Arix Bioscience (ARIX), Bioventix (BVXP), and 4basebio (4BB). These companies are all part of the "biotechnology" industry.
Avacta Group vs.
Avacta Group (LON:AVCT) and Ergomed (LON:ERGO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.
Ergomed has higher revenue and earnings than Avacta Group. Avacta Group is trading at a lower price-to-earnings ratio than Ergomed, indicating that it is currently the more affordable of the two stocks.
In the previous week, Avacta Group had 1 more articles in the media than Ergomed. MarketBeat recorded 2 mentions for Avacta Group and 1 mentions for Ergomed. Avacta Group's average media sentiment score of 0.33 beat Ergomed's score of 0.00 indicating that Avacta Group is being referred to more favorably in the media.
Ergomed received 30 more outperform votes than Avacta Group when rated by MarketBeat users. Likewise, 75.63% of users gave Ergomed an outperform vote while only 67.30% of users gave Avacta Group an outperform vote.
10.2% of Avacta Group shares are owned by institutional investors. Comparatively, 71.1% of Ergomed shares are owned by institutional investors. 32.9% of Avacta Group shares are owned by insiders. Comparatively, 18.2% of Ergomed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Ergomed has a net margin of 9.87% compared to Avacta Group's net margin of -114.45%. Ergomed's return on equity of 18.08% beat Avacta Group's return on equity.
Avacta Group has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500. Comparatively, Ergomed has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500.
Summary
Ergomed beats Avacta Group on 10 of the 14 factors compared between the two stocks.
Get Avacta Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVCT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avacta Group Competitors List
Related Companies and Tools
This page (LON:AVCT) was last updated on 1/21/2025 by MarketBeat.com Staff
Free AVCT Stock Alerts